Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
about
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).Resolution of chronic inflammatory disease: universal and tissue-specific concepts
P2860
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
@en
type
label
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
@en
prefLabel
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres.
@en
P2093
P2860
P1476
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres
@en
P2093
Anna Stanton
Ben Warner
Bu'Hussain Hayee
Cordella Brown-Clarke
Emma Johnston
Guy Chung-Faye
Ioannis Koumoutsos
Jeremy Sanderson
Johanna Bidewell-Sullivan
P2860
P304
P356
10.1136/FLGASTRO-2016-100720
P577
2016-08-10T00:00:00Z